NASDAQ NMS - GLOBAL MARKET · CBLL
+1.76% · +$0.3200 · Vol 209.7K
Ceribell Inc

Ceribell Inc

Health Care
$18.47

Veridion Score

Loading
Score loading…
Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…
REFRESHES DAILY
AI Analysis
Sovereign

Why is CBLL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Ceribell Inc
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Founded
Listed
2024
Employees
300
HQ
US

CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.

Key statistics

Real vendor fields plus Veridion-computed history. Missing fields stay blank.

Open
$18.15
Day high
$18.57
Day low
$17.99
Previous close
$18.15
52W high
$18.47
0.00% from high
52W low
$17.84
100% of range
Market cap
$700.8M
P/E
EPS
Dividend yield
Beta
Shares out
37.9M
Float
Volume
209.7K
Avg volume
VWAP
$18.32
Next earnings
Price history computed in-house
1W
+0.49%
1M
+0.49%
3M
+0.49%
1Y
+0.49%
YTD
+0.49%
SMA 50 $18.27 · above
SMA 200 $18.27 · above
52W position 100%
Veridion warehouse edge

Warehouse intelligence for CBLL.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Loading quarterly statements…
SEC Form 4 ledger

CBLL insider activity

Ceribell Inc

Score
Coverage building
Pressure
Net selling
Filings
129
Buys / sells
51 / 78
Net value
-$11.0M
Insiders
8
Named filers
CX
Chao Xingjuan
Insider
Leadership
FD
Foehr David
Insider
Leadership
MS
Manni Joseph S.
Insider
Leadership
Cluster

2 insiders bought in the last 90 days

Net pressure

Net selling: -$11.0M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-102026-06-08Chao XingjuanInsidersell$18.3323,554816,317$432KSEC Form 4
2026-06-102026-06-08Chao XingjuanInsiderbuy$4.7023,554839,871$111KSEC Form 4
2026-06-102026-06-08Chao XingjuanInsidersell$18.331,446816,317$27KSEC Form 4
2026-06-102026-06-08Chao XingjuanInsiderbuy$4.701,446817,763$7KSEC Form 4
2026-06-102026-06-08Chao XingjuanInsidersell$18.3314,000816,317$257KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 124 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Loading PTR filings…
Federal contracts

CBLL contract awards, year to date.

Public federal awards linked to this ticker.

Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CBLL in this window.
Lobbying spend

CBLL lobbying filings, year to date.

Registered lobbying filings matched to Ceribell Inc.

Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CBLL in this window.
Latest news · CBLL
Refresh interval: 5 minutes · Source: Market news insights
Loading articles…
Analyst ratings
Sovereign unlock shows live analyst consensus for CBLL.
Options
Sovereign unlock shows live options positioning for CBLL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.